Cotreatment with pegvisomant and a Somatostatin Analog (SA) in SA-responsive acromegalic patients

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 8, 2011, Pages 2405-2413

  Madsen, Michael ^a   Poulsen, Per L ^a   Ørskov, Hans ^a   Møller, Niels ^a   Jørgensen, Jens O L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; INSULIN; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; ARTHRALGIA; ARTICLE; BODY COMPOSITION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; FATIGUE; FEMALE; GLUCOSE TOLERANCE; HEADACHE; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LOW DRUG DOSE; MALE; METABOLISM; MONOTHERAPY; NAUSEA; ORAL GLUCOSE TOLERANCE TEST; PARESTHESIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWEATING; SWELLING;

ACROMEGALY; ANTINEOPLASTIC AGENTS; BODY COMPOSITION; DRUG THERAPY, COMBINATION; ENERGY METABOLISM; FEMALE; GLUCOSE INTOLERANCE; HUMAN GROWTH HORMONE; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PEPTIDES, CYCLIC; QUALITY OF LIFE; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 79961228956     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-0654     Document Type: Article

References (40)

1. Bex M, Abs R, T'Sjoen G, Mockel J, Velkeniers B, Muermans K, Maiter D 2007 AcroBel the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects. Eur J Endocrinol 157:399-409
2. Holdaway IM, Bolland MJ, Gamble GD 2008 A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159:89-95
3. Nomikos P, Buchfelder M, Fahlbusch R 2005 The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure.' Eur J Endocrinol 152:379-387 (Pubitemid 40439490)
4. Freda PU 2002 Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87:3013-3018 (Pubitemid 34816336)
5. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A 2009 Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509-1517
6. Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S 2004 Central and peripheral actions of somatostatin on the growth hormone- IGF-I axis. J Clin Invest 114:349-356 (Pubitemid 39071607)
7. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A 2009 Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 94:1500-1508
8. Hodish I, Barkan A 2008 Long-term effects of pegvisomant in patients with acromegaly. Nat Clin Pract Endocrinol Metab 4:324-332 (Pubitemid 351733473)
9. Strasburger CJ, Buchfelder M, Droste M, Mann K, Stalla GK, Saller B 2007 Experience from the German pegvisomant observational study. Horm Res 68(Suppl 5):70-73
10. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ 2002 Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23:623-646 (Pubitemid 35191626)
11. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.NEngl J Med 342:1171-1177 (Pubitemid 30211048)
12. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO 2001 Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759 (Pubitemid 33152999)
13. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML 2005 Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 90:5684-5691 (Pubitemid 41415476)
14. Lindberg-Larsen R, Møller N, Schmitz O, Nielsen S, Andersen M, Orskov H, Jorgensen JO 2007 The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab 92:1724-1728 (Pubitemid 46997178)
15. Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP, Trainer PJ 2003 Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 149:521-527 (Pubitemid 38054695)
16. Jimenez C, Burman P, Abs R, Clemmons DR, Drake WM, Hutson KR, Messig M, Thorner MO, Trainer PJ, Gagel RF 2008 Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. Eur J Endocrinol 159:517-523
17. Buchfelder M, Weigel D, Droste M, Mann K, Saller B, Brübach K, Stalla GK, Bidlingmaier M, Strasburger CJ 2009 Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur J Endocrinol 161:27-35
18. Buhk JH, Jung S, Psychogios MN, Göricke S, Hartz S, Schulz-Heise S, Klingebiel R, Forsting M, Brückmann H, Dörfler A, Jordan M, Buchfelder M, Knauth M 2010 Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab 95:552-558
19. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ 2005 Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365:1644-1646 (Pubitemid 40693415)
20. Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, Hagen C, Ørskov H 2005 Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 90:5627-5631 (Pubitemid 41415468)
21. De Marinis L, Bianchi A, Fusco A, Cimino V, Mormando M, Tilaro L, Mazziotti G, Pontecorvi A, Giustina A 2007 Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. Pituitary 10:227-232 (Pubitemid 350055033)
22. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ 2007 Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 92:4598-4601 (Pubitemid 350223432)
23. Trainer PJ, Ezzat S, D'Souza GA, Layton G, Strasburger CJ 2009 A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf) 71: 549-557
24. Neggers SJ, van der Lely AJ 2009 Somatostatin analog and pegvisomant combination therapy for acromegaly. Nat Rev Endocrinol 5:546-552
25. Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, Webb SM, van der Lely AJ 2008 Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 93:3853-3859
26. Steele R 1959 Influences of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 82:420-430
27. Debodo RC, Steele R, Altszuler N, Dunn A, Bishop JS 1963 On the hormonal regulation of carbohydrate metabolism: studies with C14 glucose. Recent Prog Horm Res 19:445-488
28. Jahoor F, Wolfe RR 1987 Reassessment of primed constant-infusion tracer method to measure urea kinetics. Am J Physiol 252:E557-E564
29. Ferrannini E 1988 The theoretical bases of indirect calorimetry: a review. Metabolism 37:287-301
30. Ørskov H, Frystyk J, Nielsen C, Hansen AT, Weeke J, Jørgensen JO 2007 Concomitant, specific determination of growth hormone and pegvisomant in human serum. Growth Horm IGF Res 17:431-434
31. Frystyk J, Dinesen B, Orskov H 1995 Non-competitive time-resolved immunofluorometric assays for determination of human insulin- like growth factor I and II. Growth Regul 5:169-176 (Pubitemid 26018330)
32. Møller N, Butler PC, Antsiferov MA, Alberti KG 1989 Effects of growth hormone on insulin sensitivity and forearm metabolism in normal man. Diabetologia 32:105-110 (Pubitemid 19096382)
33. Ørskov H, Thomsen HG, Yde H 1968 Wick chromatography for rapid and reliable immunoassay of insulin, glucagon and growth hormone. Nature 219:193-195
34. 1990 EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 16:199-208
35. Neggers SJ, de Herder WW, Janssen J, Feelders RA, van der Lely AJ 2009 Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 160:529-533
36. van der Lely AJ, Bernabeu I, Cap J, Caron P, Colao A, Marek J, Neggers S, Birman P 2011 Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol 164:325-333
37. Madsen M, Matthiesen EB, Poulsen PL, Weeke J, Astrup J, Jorgensen JO 2007 [Treatment of acromegaly in Aarhus University Hospital. A retrospective investigation of the period from 1994 to 2004]. Ugeskr Laeger 169:907-910
38. Rubeck KZ, Madsen M, Andreasen CM, Fisker S, Frystyk J, Jørgensen JO 2010 Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery. Eur J Endocrinol 163:717-726
39. Alberti KG, Christensen NJ, Christensen SE, Hansen AP, Iversen J, Lundbaek K, Seyer-Hansen K, Ørskov H 1973 Inhibition of insulin secretion by somatostatin. Lancet 2:1299-1301
40. Ho KK, Jenkins AB, Furler SM, Borkman M, Chisholm DJ 1992 Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol (Oxf) 36:271-279